Introduction:
MSD invests US$1.18 billion (€1 billion) to expand its facilities in Dunboyne and Carlow, both situated in Ireland.
Features:
The new expansion is poised to enhance global manufacturing capacity significantly, allowing to effectively address the rising need for its medicines and vaccines worldwide.
These two facilities are set to deliver substantial improvements in manufacturing capabilities, thereby empowering the global network to effectively respond to the ever-evolving global demand for vaccines and medicines.
These new facilities will result in the generation of 100 new employment opportunities. These positions will encompass a diverse array of crucial roles, including engineering, scientific research, manufacturing operations, quality control, and various other vital functions.
Both the expansion in Carlow and the opening of the new MSD Dunboyne facility hold pivotal roles in MSD's global operations. Carlow site plays a crucial role for filling and commercial supply of vaccines, biologics, and small molecule drug products, facilitating their launch and distribution.
Specifications:
Name MSD
Type Expansion
Budget US$1.18 billion (€1 billion)
